Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07081841
Enrolling by invitation Observational

AB-1005 Long-Term Follow-up Study

NCT07081841 · tracked via the Priya Life Science USA tracker
Sponsor
AskBio Inc
Phase
Observational
Started
2025-09-04
Last updated
2025-10-02

Condition(s) studied

Parkinson's DiseaseMultiple System Atrophy, Parkinson Variant

Investigational drug(s) / intervention(s)

Observation

Observation: This is an observational study in which safety laboratories and non-invasive routine clinical assessments are conducted to gauge long term safety and efficacy.

Study summary

This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005. It is intended to better understand the long-term safety of AB-1005, how well tolerated it is and how long lasting the effects are.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * PD and MSA-P participants that are or were enrolled in an interventional AB-1005 study and provide informed consent Exclusion Criteria: * There are no exclusion criteria

Primary outcome measure(s)

  • Long term safety and tolerability — Up to 10 years post surgery
    Measure of the occurrence of serious and non-serious adverse events

Trial sites (2)

FacilityCityRegionStatus
University of California San Francisco San Francisco California
Ohio State University Columbus Ohio

More AskBio Inc trials in the USA

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure Active, not recruiting
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) Active, not recruiting
Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA) Starting soon
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD) Recruiting
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) Active, not recruiting

Other trials for the same condition

Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders: Active, not recruiting
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease Active, not recruiting
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations Recruiting
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07081841 on ClinicalTrials.gov ↗ ← All trials in the USA